| Digital tumor board solutions have significant impact on case preparation RD Hammer, D Fowler, LR Sheets, A Siadimas, C Guo, MS Prime JCO Clinical Cancer Informatics 4, 757-768, 2020 | 31* | 2020 |
| Machine learning to predict tamoxifen nonadherence among US commercially insured patients with metastatic breast cancer G Yerrapragada, A Siadimas, A Babaeian, V Sharma, TJ O'Neill JCO clinical cancer informatics 5, 814-825, 2021 | 10 | 2021 |
| Natural history and burden of Huntington's disease in the UK: A population‐based cohort study H Furby, A Siadimas, L Rutten‐Jacobs, FB Rodrigues, EJ Wild European Journal of Neurology 29 (8), 2249-2257, 2022 | 9 | 2022 |
| Huntington’s disease in Israel: A population-based study using 20 years of routinely-collected healthcare data N Gavrielov-Yusim, Y Barer, M Martinec, A Siadimas, S Roumpanis, ... Journal of Huntington's Disease 10 (4), 469-477, 2021 | 5 | 2021 |
| The impact of a digital solution on case discussion time at tumor boards. D Fowler, LR Sheets, MS Prime, A Siadimas, YZ Levy, RD Hammer Journal of Clinical Oncology 37 (15_suppl), e18028-e18028, 2019 | 5 | 2019 |
| Effect of digital tumor board solutions on “failure-to-discuss” rates for patient cases during tumor boards. D Fowler, LR Sheets, MS Prime, C Guo, A Siadimas, YZ Levy, ... Journal of Clinical Oncology 37 (27_suppl), 308-308, 2019 | 3 | 2019 |
| Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis P Dillon, A Siadimas, S Roumpanis, O Fajardo, K Fitovski, N Jessop, ... Multiple Sclerosis and Related Disorders 71, 104512, 2023 | 2 | 2023 |
| Characteristics and Bleeding Behavior of Females with Mild Hemophilia A: Longitudinal Study from Picnichealth Hemophilia A Database AC Weyand, HJ Hiew, Y Jiang, A Siadimas, F Nissen, G Hanson, E Cibelli, ... Blood 140 (Supplement 1), 61-62, 2022 | | 2022 |
| Characteristics and Healthcare Utilization of Patients with Mild or Moderate Hemophilia A in the US-an Analysis from the Picnichealth Cohort A Sharathkumar, Y Jiang, HJ Hiew, A Siadimas, F Nissen, G Hanson, ... Blood 140 (Supplement 1), 2762-2763, 2022 | | 2022 |
| J04 Benchmarking enroll-HD to a phase III placebo cohort from generation HD1 to inform clinical trial planning H Furby, A Siadimas, P McColgan, L Boak, L Polito, E Neacy, JD Long, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (Suppl 1), A94-A95, 2022 | | 2022 |
| PND60 Prevalence and Incidence of Huntington's Disease in the UK (2000–2018): A UK-Based Primary Care Study H Furby, T Siadimas, L Rutten–Jacobs, A Dillon, D Oliveri, EJ Wild Value in Health 23, S634, 2020 | | 2020 |
| Survival, Mortality, and Causes of Death in Huntington's Disease Patients in the UK H Furby, L Rutten-Jacobs, T Siadimas, FB Rodrigues, EJ Wild NEUROTHERAPEUTICS 17 (SUPPL 1), 8-8, 2020 | | 2020 |
| Feasibility of addressing family burden of disease through variable linkage in US claims data H Furby, A Siadimas PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 429-429, 2020 | | 2020 |
| Effectiveness of starting emicizumab in routine clinical practice for patients with severe hemophilia A without FVIII inhibitor: results using PicnicHealth data in the United … SW Pipe, N Sharma, A Siadimas, NS Liao, G Hanson, R Chafaie, ... | | |
| Survival, mortality and causes of death in individuals with Huntington’s disease in the UK H Furby, T Siadimas, L Rutten-Jacobs, FB Rodrigues, EJ Wild | | |
